The firm has assembled a diverse portfolio consisting of product candidates that have undergone clinical testing but which the firm believes may have been underdeveloped or deprioritized at other companies.
The company aims to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, lupus, and certain life-threating viral diseases.
In June 2019, Provention Bio's share price was sent rocketing by promising results on the delaying of T1D.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze